Article Text

Download PDFPDF
Sirolimus used for treatment of retroperitoneal arteriovenous malformation in a premature neonate
  1. Chinmay Chetan,
  2. Suprabha Patnaik,
  3. Pradeep Suryawanshi and
  4. Reema Garegrat
  1. Neonatology, Bharati Vidyapeeth Deemed University Medical College, Pune, Maharashtra, India
  1. Correspondence to Dr Reema Garegrat; coolreem18{at}yahoo.com

Abstract

We describe a case of a premature infant with antenatally detected retroperitoneal arteriovenous malformation (AVM) with extensive intraspinal extension. Treatment of the malformation with embolectomy and sclerotherapy was not feasible in view of intraspinal extensions and small size of vessels of the lesion. During a trial of propranolol over 20 days, the lesion progressed in size, roughly doubling in volume and was accompanied with deranged coagulation parameters. Treatment was therefore switched to oral prednisolone and sirolimus. The steroid was stopped after 6 weeks and sirolimus was continued with serum drug level monitoring and serial imaging of the malformation. After 4 months of sirolimus, the AVM remained at the same size as at the start of treatment, thus we propose that the drug may have arrested the growth of the lesion. This case highlights the use of sirolimus in management of AVMs in infants.

  • haematology (drugs and medicines)
  • neonatal health
  • malignant and benign haematology
  • haemangioma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors CC and SP: patient care, manuscript writing; RG: patient care, collection of data; PS: manuscript editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.